# Neoadjuvant Lu-PSMA Radioligand Therapy and Ipilimumab in Men With Very High-risk Prostate Cancer

> **NCT06388369** · PHASE1,PHASE2 · TERMINATED · sponsor: **University Hospital, Essen** · enrollment: 1 (actual)

## Conditions studied

- Very High Risk Prostate Carcinoma

## Interventions

- **RADIATION:** [177Lu]Lu-PSMA-617
- **DRUG:** Ipilimumab

## Key facts

- **NCT ID:** NCT06388369
- **Lead sponsor:** University Hospital, Essen
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2025-08-25
- **Primary completion:** 2026-03-09
- **Final completion:** 2026-03-09
- **Target enrollment:** 1 (ACTUAL)
- **Why stopped:** The clinical trial has been terminated due to the revocation of funding. Although one subject was enrolled, the participant withdrew prior to receiving any treatment. No trial-related procedures generating evaluable clinical data were performed.
- **Last updated:** 2026-03-13

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06388369

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06388369, "Neoadjuvant Lu-PSMA Radioligand Therapy and Ipilimumab in Men With Very High-risk Prostate Cancer". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT06388369. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*